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1. Introduction
　Lithium has been widely used in the treatment of 
mood disorders. Its antimanic and prophylactic efects 
are of particular value in treating bipolar disorder, 
and it augments the efects of antidepressants used in 
treating refractory depression1)－4).
　cAMP is a second messenger that is generated from 
ATP through the stimulation of neurotransmitter 
receptors, such as norepinephrine and serotonin 
receptors, that are coupled to adenylyl cyclase (AC) 
via guanine nucleotide-binding proteins (G proteins). 
cAMP activates cAMP-dependent protein kinase 
(PKA), which in turn activates cAMP response 
element-binding protein (CREB). CREB enhances the 
expression of various genes, such as the gene 
encoding brain-derived neurotrophic factor (BDNF)5).
　One  of  the  proposed  mechanisms  for  the 
therapeutic efects of lithium is the induction of 
changes in the cAMP signaling system6)－8). We first 
present an overview of the available data on chronic 
lithium treatment of rats at therapeutic concentra-
tions used in humans. Lithium was shown to increase 
the AC activity by inhibiting a Gi protein in the 
frontal cortex9). It is known to increase the basal 
levels of cAMP in the frontal cortex9)－11), but not in the 
hippocampus12). In both the frontal cortex and 
hippocampus, it decreases the activity of CREB by 
inhibiting its phosphorylation13) and increases PKA 
activity14).
　cAMP  is  metabolized  by  phosphodiesterases 
(PDEs), which are classified into 7 families based on 
their afinity for cAMP and cGMP and their 
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regulatory and kinetic characteristics. The PDE4 
family is cAMP-specific, and its activity is regulated 
through  phosphorylation  and  is  increased  its 
expression by cAMP levels15). Among the 4 isoforms of 
PDE4, PDE4B is characterized by a high Km value 
and Ca2+-insensitivity.
　Previous studies have demonstrated compensatory 
changes in PDE4 expression in response to the net 
changes in cAMP signaling. Human monocytes 
activated by β-adrenoceptor agonists, AC, or PKA 
showed an increase in PDE4 expression16)－18). On the 
other hand, β-adrenoceptor antagonists decreased 
PDE4 expression in rat brain19), 20). Furthermore, 
stimulation of norepinephrine and serotonin recep-
tors in rats with chronic antidepressant treatments 
increased the expression of PDE4B mRNA in the 
frontal cortex, but not in the hippocampus8), 21). This 
increase appears to be mediated by the activation of 
CREB21). Therefore,  it  is  suggested  that  the 
expression of PDE4, especialy the mRNA expression 
of PDE4B, is a useful index of the net activity of 
cAMP signaling. One study showed that chronic 
lithium treatment increased PDE activity in rat 
frontal cortex22). However, there has been no other 
study on the efect of lithium on PDE.
　In this study, to further characterize the efects of 
lithium on cAMP signaling in relation to its 
antimanic and prophylactic efects, we examined the 
efects of lithium on the expression of PDE4B mRNA 
in rat frontal cortex and hippocampus. In addition, 
the efect of coadministration of lithium and 
imipramine was examined to elucidate the augmenta-
tion efect of lithium.
2. Materials and Methods
2.1. Animals and treatment paradigms
　Male Sprague-Dawley rats (130-160 g) (Charles 
River Japan Inc., Yokohama, Japan) were maintained 
on a 12 hour light/dark cycle with food and water 
available ad libitum.
　Rats were fed with food containing 0.1% or 0.2% 
lithium carbonate for 2 weeks (subchronic treatment) 
or 4 weeks (chronic treatment). Each of the groups 
was matched with a group of control rats fed with 
normal food. Al rats were provided free access to 
saline (0.9% NaCl) to minimize the deleterious efects 
of lithium.
　Rats were decapitated 3 hours after the last 
treatment, and the frontal cortex and hippocampus 
were dissected and frozen on dry ice for northern blot 
analysis.  Blood samples for drug measurements were 
obtained from carotid arteries.
　Food containing lithium carbonate was provided by 
Taisho Pharmaceutical Co. Ltd. (Tokyo, Japan), and 
imipramine was purchased from Sigma (Tokyo, 
Japan).
　Al animal use procedures were approved by the 
Laboratory Animal Center, Yamagata University 
School of Medicine.
2.2. Northern blot analyses
　Total RNA was isolated from the frontal cortex and 
hippocampus using the RNAqueous Smal-Scale 
Phenol-Free Total RNA Isolation Kit (Ambion, Texas, 
USA).
　The PDE4B mRNA level was determined by 
northern blot analysis according to the method of 
Takahashi et al.21). Briefly, 15 μg of total RNA was 
electrophoresed on a 1% agarose gel and transferred 
onto a nitrocelulose filter. The filter was incubated at 
65℃ for 18 hours with 32P-labeled PDE4B riboprobe, 
which was generated from PDE4B cDNA. It was then 
washed in a mixture of 2×SSC (0.15 M NaCl and 
0.015 M sodium citrate; pH 7.0) and 0.1% SDS at 65℃ 
for 20 min, and in a mixture of 0.5×SSC and 0.1% 
SDS at 65℃ for 10 min.  The 32P-labeled PDE4B 
mRNA band was visualized by autoradiography and 
quantified by the Macintosh-based NIH image 
analysis program (version 1.6.1).
　The cyclophilin mRNA level, which reflects the 
total RNA, was quantified in a similar manner, except 
that 32P-labeled cyclophilin riboprobe was not used.
　The ratio of PDE4B/cyclophilin mRNA was used for 
data analysis to correct for the diference in the 
amount of total RNA per lane.
2.3. Drug measurements
　Serum concentrations of lithium were measured by 
an atomic absorption method at JBS Inc. (Gifu, 
Japan).
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2.4. Data analyses
　The data of the 2 test groups were analyzed by 
Student's t-test, and those of al the 4 groups were 
analyzed by ANOVA and Tukey's HSD post hoc test 
using SPSS 10.0. A p value of 0.05 or less was 
regarded as statisticaly significant.
3. Results
3.1. Serum lithium concentrations
　Serum lithium concentrations in the rats treated 
with 0.2% lithium (range: 0.95-1.50 mEq/L, mean± 
SD: 1.10±0.18 mEq/L) were largely in the therapeutic 
range used in humans (0.6-1.2 mEq/L), while those in 
the rats treated with 0.1% lithium (range: 0.30-0.46 
mEq/L, mean±SD: 0.47±0.03 mEq/L) were below 
this range.
3.2. Northern blot analyses of PDE4B mRNA
　The PDE4B riboprobe hybridized with one major 
mRNA transcript of ～4.0 kb; this result was similar 
to that reported previously15). This confirmed the 
specificity of the PDE4B riboprobe used in the 
present study.
3.3. Efect of lithium on PDE4B mRNA 
expression in the frontal cortex
　The treatment with 0.1% lithium for 4 weeks 
induced no significant change in the level of PDE4B 
mRNA in the frontal cortex (Figure 1A). The mean 
level of PDE4B mRNA in the rats treated with 0.2% 
lithium for 4 weeks was slightly higher than that in 
the control rats, but this increase was not statisticaly 
significant (Figure 1C).
　The treatment with 0.2% lithium for 2 weeks did 
not change the level of PDE4B mRNA (Figure 1B).
3.4. Efect of lithium on PDE4B mRNA 
expression in the hippocampus
　The treatment with 0.1% lithium for 4 weeks 
induced no significant change in the level of PDE4B 
mRNA in the hippocampus (Figure 2A). The mean 
level of PDE4B mRNA in the rats treated with 0.2% 
lithium for 4 weeks was significantly (p<0.05) lower 
than that in the control rats (Figure 2C).
　The treatment with 0.2% lithium for 2 weeks did 
not change the level of PDE4B mRNA (Figure 2B).
Figure 1.
(A) The treatment with 0.1% lithium for 4 weeks induced no significant change in the level of PDE4B mRNA in the 
frontal cortex.
(B) The treatment with 0.2% lithium for 2 weeks did not change the level of PDE4B mRNA. 
(C) The mean level of PDE4B mRNA in the rats treated with 0.2% lithium for 4 weeks was slightly higher than that 
in the control rats without statistical significance.
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4. Discussion
4.1. Dose- and duration-dependent effects of 
lithium on PDE4B mRNA expression
　In the present study, the serum lithium concentra-
tions in the rats treated with 0.2% lithium were in the 
therapeutic range used in humans, while those in the 
rats treated with 0.1% lithium were below this range. 
 The treatment with 0.2% lithium for 4 weeks 
induced a significant change in the expression of 
PDE4B mRNA, but neither the treatment with 0.1% 
lithium for 4 weeks nor that with 0.2% lithium for 2 
weeks induced a significant change.
　In the lithium treatment of mood disorders, both 
chronic administration and therapeutic concentra-
tions are necessary for lithium to exert its antimanic 
and prophylactic efects1), 2). Therefore, we think that 
the change in the expression of PDE4B mRNA 
induced only by the treatment with 0.2% lithium for 4 
weeks is related to the therapeutic efects of lithium.
4.2. Efect of lithium on PDE4B mRNA 
expression in the frontal cortex
　Previous studies have shown that chronic lithium 
treatment increased the AC activity9), basal levels of 
cAMP9)－11), the PDE activity22), and the PKA activity14) 
in the rat frontal cortex. Further, one study showed 
that lithium decreased CREB activity13). Therefore, 
the net change in cAMP signaling induced by lithium 
in this brain region has remained unclear.
　In the present study, chronic lithium treatment 
slightly increased the expression of PDE4B mRNA in 
the frontal cortex, but this increase was not 
statisticaly significant. This result, which was 
obtained using the sensitive index of the net activity 
of cAMP signaling, suggests that the efect of lithium 
on cAMP signaling in this brain region is negligible or 
slight at best. This finding is in contrast to the 
previous finding that antidepressants markedly 
increase  cAMP  signaling  in  rat  frontal  cortex21).  
Therefore, an increase in cAMP signaling in this 
brain region is likely to be associated with an 
antidepressant efect, but not with antimanic or 
prophylactic efects.
4.3. Efect of lithium on PDE4B mRNA 
expression in the hippocampus
　In previous studies, chronic lithium treatment did 
not change basal levels of cAMP in rat hippocam-
pus12).  However, the PKA activity increased14), while 
the CREB activity decreased13). In the present study, 
Figure 2.
(A) The treatment with 0.1% lithium for 4 weeks induced no significant change in the level of PDE4B mRNA in the 
hippocampus. 
(B) The treatment with 0.2% lithium for 2 weeks did not change the level of PDE4B mRNA.
(C) The mean level of PDE4B mRNA in the rats treated with 0.2% lithium for 4 weeks was significantly (*p<0.05) 
lower than that in the control rats.
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chronic lithium treatment significantly decreased the 
expression of PDE4B mRNA in the hippocampus.
　The most plausible explanation for these seemingly 
discordant findings is as folows. Chronic lithium 
treatment tends to decrease basal levels of cAMP 
since it inhibits the release of serotonin in rat 
hippocampus23). PKA activity increases14) to compen-
sate for this tendency, but the compensatory change is 
not suficient and the net cAMP signaling remains 
compromised, as reflected by the decrease in CREB 
activity13) and the decrease in the expression of 
PDE4B mRNA observed in the present study. The 
decrease in the expression of PDE4B normalizes the 
basal levels of cAMP.
　Thus, the present study suggests that chronic 
lithium treatment reduces cAMP signaling in the 
hippocampus. This efect may be related to the 
antimanic and prophylactic efects of lithium. 
However, the mechanism through which lithium 
attenuates cAMP signaling remains unclear and 
therefore should be clarified in further studies.
　It is noteworthy that lithium which has diferent 
net efects on cAMP signaling in the hippocampus 
and frontal cortex as clarified here increases the PKA 
activity in both brain regions14). One possible 
explanation is that, in contrast to the compensatory 
mechanism in the hippocampus, in the frontal cortex 
lithium by inhibiting a Gi protein9) increases basal 
level of cAMP9)－11) which directly leads to increased 
PKA activity14).
5. Limitations in present study
　There are two possible limitations in the present 
study. Firstly, there was large variability in the 
expression of PDE4B mRNA in rat brains even in the 
control groups, which may reflect the limitation of the 
methodology we adopted.  Also, the number of rats 
used might be too smal. Therefore, the slight 
decrease in the group treated with 0.2% lithium for 4 
weeks compared with the control group in the 
hippocampus should be interpreted cautiously, and 
the definite conclusion awaits a replication study with 
a more sophisticated methodology.
　Secondly, behavioral changes of rats were not 
evaluated. In relation to this, the scrutinizing of the 
literature reveals that no study has examined the 
relationship  between  the  PDE4B  change  and 
behavioral changes in animals or psychomotor 
changes in humans. Taken together, if the PDE4B 
change to the degree observed in the present study is 
actualy related to clinical efects of lithium remains 
unclear. We suggest that behavioral monitoring 
should be included in the protocol of the replication 
study mentioned above.
6. Conclusions
　Chronic treatment significantly decreased the 
expression of PDE4B mRNA in the hippocampus of 
rats treated with 0.2% lithium. This result suggests 
that chronic lithium treatment reduces the net 
activity of the cAMP signaling system in the 
hippocampus; furthermore, since these efects are 
dose- and duration-dependent, they may be related to 
the clinical antimanic and prophylactic efects of 
lithum.
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